EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease

Sina Rashedi, Mohammad Keykhaei, Alyssa Sato, Philippe Gabriel Steg, Gregory Piazza, John W Eikelboom, Renato D Lopes, Marc P Bonaca, Satoshi Yasuda, Hisao Ogawa, Satoshi Shizuta, Takeshi Kimura und 8 weitere

Journal of the American College of Cardiology · 2025-03 · 85 (11) · 1189-1203

DOI: 10.1016/j.jacc.2024.12.030 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of the American College of Cardiology, 2025-03. Verfasst von Sina Rashedi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Platelet Aggregation Inhibitors, Coronary Artery Disease. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The optimal long-term antithrombotic strategy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains uncertain. Individual randomized controlled trials (RCTs) had variations in their reported results and were not powered for effectiveness outcomes. OBJECTIVES: This study aimed to pool the results of RCTs comparing the effectiveness and safety of oral anticoagulation (OAC) monotherapy vs OAC plus single antiplatelet therapy (SAPT) in patients with AF and stable CAD. METHODS: We systematically searched PubMed, Embase, and ClinicalTrials.gov until September 09, 2024. The primary effectiveness outcome was a composite of myocardial infarction, ischemic stroke, systemic embolism, or death. The primary safety outcome was major bleeding. We obtained unpublished results from principal investigators of the included RCTs, as needed, to calculate pooled HRs and 95% CIs and to perform prespecified subgroup analyses. RESULTS: Among 690 screened records, 4 RCTs with 4,092 randomized patients were included (2 using edoxaban, 1 using rivaroxaban, and 1 using any oral anticoagulant; mean age 73.9 years, 20.1% women). The median follow-up durations ranged from 12 to 30 months (overall estimated weighted mean follow-up of 21.9 months). There were no statistically significant differences between OAC monotherapy vs OAC plus SAPT in the primary effectiveness outcome (7.3% vs 8.2%; HR: 0.90; 95% CI: 0.72-1.12), myocardial infarction (1.0% vs 0.7%; HR: 1.51; 95% CI: 0.75-3.04), ischemic stroke (1.9% vs 2.1%; HR: 0.89; 95% CI: 0.57-1.37), all-cause death (4.2% vs 5.3%; HR: 0.94; 95% CI: 0.49-1.80), or cardiovascular death (2.4% vs 3.0%; HR: 0.79; 95% CI: 0.54-1.15). OAC monotherapy was associated with a lower risk of major bleeding than OAC plus SAPT (3.3% vs 5.7%; HR: 0.59; 95% CI: 0.44-0.79). Subgroup analyses did not show significant interactions for effectiveness but suggested that the magnitude of bleeding reduction may be greater among men (Pinteraction = 0.03) and among patients with diabetes mellitus (Pinteraction = 0.04). CONCLUSIONS: In patients with AF and stable CAD, OAC monotherapy, compared with OAC plus SAPT, was not associated with a statistically significant increased risk of ischemic events but resulted in a significantly reduced risk of bleeding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsPlatelet Aggregation InhibitorsCoronary Artery DiseaseHumansRandomized Controlled Trials as TopicDrug Therapy, CombinationHemorrhage

Stichwörter der Autor:innen

anticoagulantatrial fibrillationbleedingcoronary artery diseaseischemiaplatelet aggregation inhibitors

Substanzen

AnticoagulantsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
  • Université Paris-Cité, INSERM U1148, FACT French Alliance for Cardiovascular Trials, AP-HP Hopital Bichat, Paris, France.
  • Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachuset…
  • Department of Medicine, Population Health Research Institute, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, USA.

Zitieren

APA

Rashedi, S., Keykhaei, M., Sato, A., Steg, P. G., Piazza, G., Eikelboom, J. W., Lopes, R. D., Bonaca, M. P., Yasuda, S., Ogawa, H., Shizuta, S., Kimura, T., Okumura, Y., Andreotti, F., Bertoletti, L., Stone, G. W., Mehran, R., Cohen, D. J., Lip, G. Y. H., & Bikdeli, B. (2025). Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease. Journal of the American College of Cardiology, 85(11), 1189-1203. https://doi.org/10.1016/j.jacc.2024.12.030

Vancouver

Rashedi S, Keykhaei M, Sato A, Steg PG, Piazza G, Eikelboom JW, et al. Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease. Journal of the American College of Cardiology. 2025;85(11):1189-1203. doi:10.1016/j.jacc.2024.12.030

BibTeX
@article{Rashedi2025,
  author = {Rashedi, Sina and Keykhaei, Mohammad and Sato, Alyssa and Steg, Philippe Gabriel and Piazza, Gregory and Eikelboom, John W and Lopes, Renato D and Bonaca, Marc P and Yasuda, Satoshi and Ogawa, Hisao and Shizuta, Satoshi and Kimura, Takeshi and Okumura, Yasuo and Andreotti, Felicita and Bertoletti, Laurent and Stone, Gregg W and Mehran, Roxana and Cohen, David J and Lip, Gregory Y H and Bikdeli, Behnood},
  title = {Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease},
  journal = {Journal of the American College of Cardiology},
  year = {2025},
  volume = {85},
  number = {11},
  pages = {1189--1203},
  doi = {10.1016/j.jacc.2024.12.030}
}
Kostenlos starten →